# Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Source: https://onco.cc/trials/nct04486833/  
OnCo record `nct04486833` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Osimertinib in non-small-cell lung cancer, run by Genprex, Inc., now recruiting.

## Summary

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib is a phase 1/2 interventional study registered as NCT04486833 by Genprex, Inc., with 158 participants planned, started 2021-09-03 and due to reach its primary completion in 2028-03. Interventions recorded: quaratusugene ozeplasmid, osimertinib and Platinum-Based Chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04486833
- Phase: 1/2
- Setting: A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
- Sponsor: Genprex, Inc.
- Enrolled: 158

## Sources

- ClinicalTrials.gov NCT04486833: https://clinicaltrials.gov/study/NCT04486833

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [Genprex](https://onco.cc/companies/genprex/)

---
JSON: https://onco.cc/api/v1/entities/nct04486833.json